IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:		on of:	Dean Y. Li		
				Confirmation No.	
Application No.:			10/519342	2504	
Filed:			September 21, 2005		
For:			METHODS AND COMPOSITIONS FOR MANUPULATING THE GUIDED NAVIGATION OF ENDOTHELIAL TUBES DURING ANGIOGENESIS		
Group Art Unit:			1647		
Examiner:			David S. Romeo		
Attorn	ey Docl	ket No.:	38623/19.1		
Date:			September 24, 2009		
то ті			MENTAL INFORMATION DISCLOSURE SOLUTION ONER FOR PATENTS:	STATEMENT	
10 11	IL CON	11011001	ONLKTOKTATENTS.		
1.			e duty of disclosure, documents listed on the a equivalent) are presented for the Examiner's		
			of listed U.S. patents and U.S. patent applica d for submission. (37 C.F.R. § 1.98(a)(2)(ii))		
	\boxtimes		of listed foreign patent documents and/or noted. (37 C.F.R. § 1.98(a)(2))	n-patent literature are	
		PTO-1- U.S. Pa applica inform	of the documents listed at (sheet/cite no.)449 (or equivalent) are omitted because (1) thatent Application No, filed, filed	ey are already of record in , on which this J.S.C. § 120; and (2) any tion of Application	
		attache	of copending U.S. Patent Application No, for, listed at (sheet/c d Form PTO-1449 (or equivalent), is encluded if available via IFW. 1287 OG 1	ite no.) of the osed / is omitted.	
2.	This information		on disclosure statement is being submitted (cl	neck box a., b., or c.):	
	a.		Within three months of the filing date of a na of the national stage in an international application of a first Office action on the merits; first Office action after the filing of a request	cation; or before the or before the mailing of a	

			1.97(e)) is required.); or			
	b.	\boxtimes	After the period set forth in paragraph 2a, but before the mailing date of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or ii.)				
		i.		The \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is paid herewith, or			
		ii.		A statement specified by 37 CFR 1.97(e) is set forth below; or			
	c.		before 1.97(e)	he mailing date of a final action or notice of allowance and on or payment of the issue fee. A statement specified by 37 CFR is set forth below. Enclosed is the \$180.00 information cure statement processing fee set forth in 37 CFR 1.17(p).			
3.	Fee Pa	ee Payment					
	a.		A chec	k in the amount of \$ is enclosed.			
	b.	\boxtimes	Payme	nt by credit card.			
	c.			charge our Deposit Account No in the amount of			
	d.		which	ommissioner is hereby authorized to charge any additional fees may be required in connection with filing of these papers, or overpayment to Deposit Account No. 502375.			
4.	If a statement specified by 37 CFR 1.97(e) is required, the attorney or agent signing below hereby states that:						
		was fin	each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or				
		no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.					

examination under 37 CFR 1.114. (No statement under 37 CFR

5.	A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is set forth below.				
	Respectfully submitted,				
	By: /Samuel E. Webb/				
	Registration No. 44.394				

STOEL RIVES LLP 600 University Street, Suite 3600 Seattle, WA 98101 Telephone: (206) 624-0900 Facsimile: (206) 386-7500